Seizures Drug Pipeline Analysis Report 2025
Description
According to the World Health Organization, approximately 50 million people have epilepsy globally. It is one of the most common neurological diseases. As per data suggested by the Centers for Disease Control and Prevention, in the United States, 3 million people suffer from epilepsy. There has been a significant emphasis on developing effective seizure therapeutic products for neurological disorders as major companies and institutions are working towards innovative treatments for seizures.
Report Coverage
The Seizures Drug Pipeline Report by Expert Market Research gives comprehensive insights into seizures drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for seizures. The seizures report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from seizures.
The detailed seizures analytical perspective of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to seizures are covered.
Seizures Drug Pipeline Outlook
A seizure is a sudden and uncontrolled burst of electrical activity in the brain, which can cause changes in movements, behavior, and levels of consciousness. It can occur after a head injury or a stroke and be caused by an infection such as meningitis. There are multiple types of seizures. The type of seizure varies from where they begin in the brain. The frequency of most seizures lasts from 30 seconds to two minutes. The symptoms of seizure include temporary confusion, staring spells, jerking movements of the legs and arms, loss of consciousness or awareness, and cognitive changes.
Seizures treatment includes the use of anti-seizure medicines. Different options for anti-seizure medicine are available in the market. Companies are developing innovative treatments to manage seizures. For instance, a phase III clinical trial study is being conducted to assess the effects of ZX008 when used as adjunctive therapy for the treatment of seizures. Several seizure therapeutic products in the pipeline are being developed by major pharma companies which has impacted the pipeline analysis for seizures.
Seizures – Drug Pipeline Therapeutic Assessment
This section of the seizures report covers the analysis of seizure drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
EMR’s seizures clinical assessment of products covers 50+ drug analyses based on drug classes:
EMR’s seizures clinical assessment covers 50+ drug analyses based on the route of administration.
The seizures pipeline insight covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with approximately 300 trials are currently in phase III.
Seizures – Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under seizure pipeline analysis include sodium channel blockers, calcium channel blockers, gamma-aminobutyric acid (GABA), enhancers glutamate receptor antagonists. Sodium channel blockers inhibit voltage-gated sodium channels help in reducing neuronal excitability and prevent the spread of seizure. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for seizures.
Seizures Clinical Trials Assessment – Competitive Dynamics
The EMR report for the seizures pipeline landscape covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in seizures clinical trials:
Cannabidiol Oral Solution
Cannabidiol oral solution is currently under phase II and is sponsored by INSYS Therapeutics Inc. The study is being conducted to assess the safety and tolerability of three multiple ascending doses of cannabidiol oral solution in patients.
RWJ-333369
A phase III study, sponsored by SK Life Science, Inc. is evaluating the safety and effectiveness of the drug to manage partial epilepsy in patients who have poor seizure control.
Retigabine
GlaxoSmithKline is developing the drug and it is currently under phase III. The study is investigating the safety and efficacy of seizures treatment retigabine dosed at 900 mg/day and 600 mg/day in epilepsy patients.
Reasons To Buy This Report
The Seizures Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for seizures. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into seizures collaborations, market trends, regulatory environments, and potential growth opportunities within seizure drug pipeline insights.
Key Questions Answered in the Seizures – Pipeline Assessment Report
Global Tonic-Clonic Seizures Treatment Market
North America Epilepsy Drugs Market
Epilepsy Drugs Market
Report Coverage
The Seizures Drug Pipeline Report by Expert Market Research gives comprehensive insights into seizures drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for seizures. The seizures report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from seizures.
The detailed seizures analytical perspective of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to seizures are covered.
Seizures Drug Pipeline Outlook
A seizure is a sudden and uncontrolled burst of electrical activity in the brain, which can cause changes in movements, behavior, and levels of consciousness. It can occur after a head injury or a stroke and be caused by an infection such as meningitis. There are multiple types of seizures. The type of seizure varies from where they begin in the brain. The frequency of most seizures lasts from 30 seconds to two minutes. The symptoms of seizure include temporary confusion, staring spells, jerking movements of the legs and arms, loss of consciousness or awareness, and cognitive changes.
Seizures treatment includes the use of anti-seizure medicines. Different options for anti-seizure medicine are available in the market. Companies are developing innovative treatments to manage seizures. For instance, a phase III clinical trial study is being conducted to assess the effects of ZX008 when used as adjunctive therapy for the treatment of seizures. Several seizure therapeutic products in the pipeline are being developed by major pharma companies which has impacted the pipeline analysis for seizures.
Seizures – Drug Pipeline Therapeutic Assessment
This section of the seizures report covers the analysis of seizure drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
EMR’s seizures clinical assessment of products covers 50+ drug analyses based on drug classes:
- Sodium Channel Blockers
- Calcium Channel Blockers
- Gamma-Aminobutyric Acid (GABA)
- Enhancers Glutamate Receptor Antagonists
EMR’s seizures clinical assessment covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The seizures pipeline insight covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials, with approximately 300 trials are currently in phase III.
Seizures – Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under seizure pipeline analysis include sodium channel blockers, calcium channel blockers, gamma-aminobutyric acid (GABA), enhancers glutamate receptor antagonists. Sodium channel blockers inhibit voltage-gated sodium channels help in reducing neuronal excitability and prevent the spread of seizure. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for seizures.
Seizures Clinical Trials Assessment – Competitive Dynamics
The EMR report for the seizures pipeline landscape covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in seizures clinical trials:
- GSK PLC
- Eisai Co., Ltd.
- Novartis AG
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Neurelis, Inc.
- Others
Cannabidiol Oral Solution
Cannabidiol oral solution is currently under phase II and is sponsored by INSYS Therapeutics Inc. The study is being conducted to assess the safety and tolerability of three multiple ascending doses of cannabidiol oral solution in patients.
RWJ-333369
A phase III study, sponsored by SK Life Science, Inc. is evaluating the safety and effectiveness of the drug to manage partial epilepsy in patients who have poor seizure control.
Retigabine
GlaxoSmithKline is developing the drug and it is currently under phase III. The study is investigating the safety and efficacy of seizures treatment retigabine dosed at 900 mg/day and 600 mg/day in epilepsy patients.
Reasons To Buy This Report
The Seizures Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for seizures. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into seizures collaborations, market trends, regulatory environments, and potential growth opportunities within seizure drug pipeline insights.
Key Questions Answered in the Seizures – Pipeline Assessment Report
- What is the current landscape of Seizures pipeline drugs?
- Which companies/institutions are developing Seizures emerging drugs?
- How many phase II drugs are currently present in Seizures pipeline drugs?
- Which company is leading the Seizures pipeline development activities?
- What is the current Seizures therapeutic assessment?
- What are the opportunities and challenges present in the Seizures drug pipeline landscape?
- What is the efficacy and safety profile of Seizures pipeline drugs?
- Which companies/institutions are involved in Seizures collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in Seizures?
Global Tonic-Clonic Seizures Treatment Market
North America Epilepsy Drugs Market
Epilepsy Drugs Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology and Assumptions
- 2 Executive Summary
- 3 Overview of Seizures
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Seizures: Epidemiology Snapshot
- 5.1 Seizures Incidence by Key Markets
- 5.2 Seizures– Patients Seeking Treatment in Key Markets
- 6 Seizures: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Seizures: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Seizures, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Seizures Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Seizures Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Buccal Midazolam
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Carbamazepine
- 10.2.3 Pregabalin
- 10.2.4 Other Drug
- 11 Seizures Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 CVL-865
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Perampanel
- 11.2.3 Other Drugs
- 12 Seizures Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Topiramate
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Oxcarbazepine
- 12.2.3 Divalproex Sodium
- 12.2.4 Other Drugs
- 13 Seizures Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Drug 2
- 13.2.3 Other Drugs
- 14 Seizures, Key Drug Pipeline Companies
- 14.1 GSK PLC
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Eisai Co., Ltd.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Novartis AG
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Neurelis, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
